Skip to main content

MAPS Users

MAPS software was replaced with Bamboo Health’s PMP AWARxE software, effective April 4, 2017.

Bamboo Health provides the nation's most comprehensive platform for early identification, prevention and management of substance use disorders. PMP AWARxE is a prescription monitoring solution that provides state government agencies with accurate, real-time data, compliant with their regulations. Active in 43 states and territories, Bamboo Health’s prescription monitoring solutions lead the nation in prescription data monitoring.

Michigan’s new PMP AWARExE site allows licensed professionals (and their delegates) to access data. This is the same site that law enforcement and benefit plan managers use to request data from MAPS.

If you require technical support with the new site, please contact the Bamboo Health Customer First Center at 1-844-364-4767.


MAPS enables practitioners to determine if patients are receiving controlled substances from other providers and to assist in the prevention of prescription drug abuse. Registration to MAPS online is easy and only takes a few minutes. MAPS online is available 24/7 to request MAPS reports.

Register Here

Watch the video below for a step-by-step tutorial to register with the new MAPS.

Law Enforcement, Government Agencies, and Benefit Plan Managers

MAPS allows law enforcement, government agencies, and benefit plan managers to register online to submit requests for MAPS data. MAPS requires each user to submit a completed Registration Form to attach to their online registration. MAPS registration and data requests are reviewed on an individual basis during normal business hours.

Important Documents

Registration Form
Registration Tutorial
Quick Reference – Patient Search


Telephone: 517-241-0166

Fax: 517-241-5072



The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies until August 31, 2023. Learn how to start the integration process.


If your question(s) pertain to the new opioid legislation, we encourage you to review the recently-released FAQs. Additional questions or concerns can be addressed by contacting MAPS.